The Study
Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
This study shows that when people took a weight-loss drug, their uric acid levels went down—and most of that drop happened because they lost weight. But it didn’t test if this actually stops gout attacks, so we can’t say for sure it prevents gout.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study looked at a drug that helps people lose weight and found it also lowers a chemical in the blood called uric acid, which can cause gout.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 572 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This drop is similar to what low-dose gout medication achieves, meaning weight loss from this drug could help prevent gout flares.
- 2People who took the highest dose lost weight and saw their uric acid drop by almost 1 mg/dL — about 5 times more than those on placebo.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Annals of the rheumatic diseases
Year
2025
Authors
N. Sattar, Sabrina Scilletta, A. Stefanski, Hui Wang, Jack W Daly, B. Linetzky
Related Content
Claims (6)
In adults with obesity or overweight, a weekly injection of tirzepatide at doses of 5, 10, or 15 mg for 72 weeks lowers blood uric acid levels more than a placebo, with the highest dose producing the greatest reduction.
In adults with obesity or overweight, 72.7% of the reduction in serum uric acid caused by tirzepatide is due to loss of body weight, and the rest is from other effects of the drug.
Tirzepatide lowers serum uric acid levels in obese individuals, and this effect is consistent whether their initial body weight or uric acid levels were high or low.
Tirzepatide lowers serum uric acid levels in people with obesity or overweight, and the amount of reduction is similar in men and women.
Weight loss caused by GLP-1 receptor agonists is associated with lower levels of uric acid in the blood.
Tirzepatide lowers uric acid in the blood by the same amount as low-dose allopurinol in people with obesity.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.